Novartis continued its mega-investments in China by announcing it will spend $250 million to expand its global technical center in Changshu, and it will also pay $125 million to buy a 85% stake in a privately held China vaccine company, Zhejiang Tianyuan. Yesterday, Novartis said it would spend $1 billion over the next five years to expand its R&D facility in Shanghai, one of the institutions around the world that comprise the Novartis Institutes for BioMedical Research (NIBR). More details...

Stock Symbol: (NYSE: NVS)